PCSK1N and synucleinopathy: These early protocols, initially developed for prion disease, established the foundation for adapting SAAs to other proteinopathies, such as tauopathies [43, 44] and synucleinopathies [7, 9, 31, 45], where the aggregation of tau and aSYN, respectively, play central roles in disease progression.